Episteme Prognostics, Inc. — SEC Form D Filing

Episteme Prognostics, Inc. filed an SEC Form D on September 4, 2026, reporting $5.09M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 4, 2026
Amount reported
$5.09M
Round stage
Series A, inferred from the $5.09 million raised which represents a typical early-institutional round size required to fund clinical validation studies in the biotechnology sector.
Industry
Biotechnology
Website
https://epistemeprognostics.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Oncologists and clinicians lack precise, molecular-level predictive tools to accurately forecast disease progression and patient response to specific therapies.

Solution

Episteme Prognostics develops advanced molecular prognostic assays and machine learning-driven biomarker platforms to predict patient outcomes and guide personalized treatment selection.

Why now

Recent advancements in high-throughput genomic sequencing and artificial intelligence now allow for the rapid, cost-effective identification of complex prognostic signatures.

Source: SEC EDGAR Form D filing